Immunotech Biopharm Ltd (HK:6978) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Immunotech Biopharm Ltd has announced the transfer of its RMB300 million Convertible Bonds from Tasly (Hong Kong) Pharmaceutical Investment Limited to Tibet Jiaze Venture Capital Co., Ltd, pending several conditions. The transfer reflects strategic movements in the financial market and highlights the venture capital interest in biotech industries. Upon completion, the bonds’ terms will remain unchanged, maintaining the financial stability of the arrangement.
For further insights into HK:6978 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue